colorectal cancer

Showing 15 posts of 21 posts found.

FDA approves Taiho’s Lonsurf for metastatic colorectal cancer treatment

August 3, 2023
Medical Communications FDA, Lonsurf, Oncology, colorectal cancer, mCRC, taiho

Taiho Oncology and Taiho Pharmaceutical have announced that the US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil) as …

Takeda and HUTCHMED’s cancer drug shown to prolong overall survival

June 16, 2023
Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …


MSD’s Keytruda hits Phase 3 main goal in first-line colorectal cancer sub-population

April 3, 2020
Medical Communications, Research and Development MSD, colorectal cancer, keytruda, pharma

MSD has lifted the veil on new Phase 3 for its blockbuster immunotherapy Keytruda, showing that the anti-PD-1 therapy met …


Pierre Fabre’s triplet therapy makes strong showing in BRAF V600E-mutant metastatic colorectal cancer

July 8, 2019
Research and Development, Sales and Marketing Cancer, Pierre Fabre, colorectal cancer, pharma

Pierre Fabre chose the European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain, to …

Array Biopharma’s Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype

May 22, 2019
Research and Development Array Biopharma, Braftovi, Cancer, colorectal cancer, pharma

Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it …


Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer

July 4, 2016
Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study

Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …


Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016
Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …


Merck receives CE Mark approval for new liquid biopsy test for colorectal cancer

April 6, 2016
Medical Communications, Research and Development, Sales and Marketing CE Mark, Merck, biomarker, biopsy, colorectal cancer, liquid biopsy, ras, sysmex inostics

Merck (ETR: MRK) has announced that their new liquid biopsy RAS biomarker test for metastatic colorectal cancer, developed in collaboration …


Incyte to stop Jakafi pancreatic, colorectal cancer drug trials

February 11, 2016
Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …


Merck’s Erbitux approved for NHS Wales

January 5, 2016
Manufacturing and Production, Sales and Marketing Erbitux, Merck, cetuximab, colorectal cancer, metastatic colorectal cancer

The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS …

Sanofi’s colorectal cancer drug gains FDA approval

August 6, 2012
Sales and Marketing FDA, Sanofi, Zaltrap, colorectal cancer

The FDA has approved Sanofi and Regeneron’s new oncology drug Zaltrap for aggressive forms of colorectal cancer.Zaltrap (ziv-aflibercept), in combination …

FDA grants priority review for Sanofi cancer drug

April 5, 2012
Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer

The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …

Latest content